Biomarin Pharmaceutical Inc
BMRN: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$96.00 | Rtvdctl | Hktjzdvy |
BioMarin Earnings: Strong Voxzogo Growth and Roctavian Launch Poised to Begin
BioMarin’s second-quarter revenue increased 12% to nearly $600 million, consistent with sales in the first quarter, and we think this puts the firm in a good position to meet our forecast of roughly $2.4 billion for the full year, as ongoing launches of achondroplasia drug Voxzogo and hemophilia A gene therapy support the firm's narrow moat rating. We’re maintaining our $96 fair value estimate.